Achieve Life Sciences Inc... (ACHV)
| Bid | 2.73 |
| Market Cap | 98.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.98M |
| EPS (ttm) | -1.12 |
| PE Ratio (ttm) | -2.56 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 2.97 |
| Volume | 98,245 |
| Avg. Volume (20D) | 236,143 |
| Open | 3.05 |
| Previous Close | 3.07 |
| Day's Range | 2.85 - 3.04 |
| 52-Week Range | 2.84 - 5.59 |
| Beta | 1.68 |
About ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol....
Analyst Forecast
According to 5 analyst ratings, the average rating for ACHV stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 318.85% from the latest price.
3 months ago · seekingalpha.com
Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call TranscriptAchieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - ...